ICKSMCB 2018 / 2018 International Conference of the Korean Society for Molecular and Cellular Biology / September 17(Mon)-19(Wed), 2018 / COEX, Seoul, Korea

Nobel Laureate Lecture

HOME > Program > Luncheon Symposium

Bio-Techne : Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) in Immunotherapy (Essence Medical Inc.)

September 19 (Wed), 12:20-13:10, Rm. 308

Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) in Immunotherapy

Dr. Marco Ruella
Department of Medicine Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania, USA

Anti-CD19 chimeric antigen receptor T cells (CART19) are now an FDA-approved drug for relapsed B-cell acute leukemia and diffuse large B cell lymphoma. The approval by the FDA of the first adoptive T cell therapy, the UPenn/Novartis CART19 (CTL019), represents a huge achievement for cancer treatment and paves the way to the use of the CART technology in other cancers and in combination with other agents. Intense scientific research is currently ongoing with the goal of improving safety, increasing response rates and avoiding relapses. In his talk Dr. Ruella will summarize the key milestones in CART therapy, the technologies that have supported these advancements and draw his view on future directions and perspectives for the field.